Clinical trials: Steroid Refractory
Immune Thrombocytopenic Purpura (ITP)
A Study to Assess the Ability of Eltrombopag to Induce Sustained Response Off Treatment in Subjects With ITP
The purpose of this trial was to assess the ability of eltrombopag to induce sustained treatment-free remission in immune thrombocytopenia purpura (ITP) subjects who relapsed or failed to respond to an initial treatment with…
- Trial name
- TAPER (NCT03524612)
- Testing
- eltrombopag
- Where
- 32 sites in United States, Austria and 13 more
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Graft vs Host Disease
A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)
The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and…
- Trial name
- NCT03474679
- Testing
- Ibrutinib
- Where
- 15 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Graft-Versus-Host Disease
Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease
This study will evaluate the response rate to treatment with pentostatin in steroid-refractory acute graft versus host disease.
- Trial name
- NCT00201786
- Testing
- Pentostatin
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Ulcerative Colitis
Basiliximab in Moderate to Severe Ulcerative Colitis
The purpose of this study is to assess the safety, effectiveness and pharmacokinetics of two levels of intravenous basiliximab in ulcerative colitis, compared to placebo.
- Trial name
- NCT00430898
- Testing
- Basiliximab
- Where
- 68 sites in United States, Belgium and 7 more
- Volunteers
- 181 people
- Sponsor
- Cerimon Pharmaceuticals
Hematopoietic and Lymphoid Cell Neoplasm, Steroid Refractory Graft Versus Host Disease
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
This early phase I trial is to find out the effect of adding cord blood tissue-derived mesenchymal stromal cells (cb-MSCs) to ruxolitinib in treating patients with acute graft versus host disease that does not respond to steroid…
- Trial name
- NCT04744116
- Testing
- Cellular Therapy, Ruxolitinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Graft vs Host Disease
Jaktinib for Steroid-Refractory Acute Graft-Versus-Host Disease
Graft-versus-host disease (GVHD) is a common severe complication and a primary cause of mortality following allogeneic hematopoietic stem cell transplantation (allo-HSCT).Previous studies have demonstrated that the JAK/STAT…
- Trial name
- NCT07885228
- Testing
- Jaktinib
- Where
- 24 sites in China
- Volunteers
- 49 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Ulcerative Colitis
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.
- Trial name
- NCT00279422
- Testing
- visilizumab
- Where
- 70 sites in United States, Australia and 12 more
- Volunteers
- 127 people
- Sponsor
- Facet Biotech
Immune-mediated Colitis (IMC), Immune-related Dermatitis
Healthy-donor Microbiome MTP-101-C in Steroid Relapse/Refractory Immune-related Cutaneous Adverse Events (irCAEs) and Immune-mediated Colitis (IMC)
Multiple retrospective studies suggest that the administration of corticosteroids to treat irAEs is safe, and does not compromise efficacy of ICI therapy in cancer patients.
- Trial name
- FMT-ELIMINATE (NCT06499896)
- Testing
- MTP-101-C
- Where
- United States
- Sponsor
- Diwakar Davar
Graft vs Host Disease
Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether the combination of ruxolitinib and etanercept provides superior efficacy compared with ruxolitinib monotherapy in patients with severe…
- Trial name
- RESCUE (NCT07184853)
- Testing
- Ruxolitinib (JAKAVI®), Etanercept (Enbrel)
- Where
- China
- Volunteers
- 122 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Graft Versus Host Disease
Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT
This is a phase I trial of LDE225 for the treatment of steroid-refractory chronic Graft Versus Host Disease (GVHD).
- Trial name
- NCT02086513
- Testing
- LDE225
- Where
- 3 sites in United States
- Volunteers
- 17 people
- Sponsor
- Massachusetts General Hospital
Graft Versus Host Disease
Allogenic Bone Marrow Mesenchymal Stem Cells Infusion in Patients With Steroid-refractory GVHD
Graft versus host disease is a serious and often life-threatening complication in allogeneic haematopoietic stem cell transplantation.
- Trial name
- NCT02824653
- Testing
- Mesenchymal Stem Cells
- Where
- Pakistan
- Volunteers
- 10 people
- Sponsor
- National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Acute GvHD
Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)
The purpose of this study is to determine the safe and tolerable, biologically active, and potentially effective doses(s) of ALD518 in subjects with acute GVHD, who have failed to respond to glucocorticosteroids, for further…
- Trial name
- ALD518-010 (NCT01530256)
- Testing
- ALD518
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- CSL Behring
Myasthenia Gravis, Autoimmune Diseases
Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis
This study is designed to explore the efficacy and safety of Telitacicept combined with low-dose steroids for the treatment of refractory MG, and to investigate related biomarkers such as immunoglobulins, BlyS/APRIL, and AChR-Ab…
- Trial name
- NCT06723548
- Testing
- Telitacicept
- Volunteers
- 30 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Active Rheumatoid Arthritis
Pulse Steroid Injection in Refractory Rheumatoid Arthritis
Remission or low disease activity in active rheumatoid arthritis
- Trial name
- NCT06456489
- Testing
- Solumedrol
- Where
- Egypt
- Volunteers
- 268 people
- Sponsor
- Sohag University
Steroid Refractory Graft Versus Host Disease
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
The purpose of this study is to determine the efficacy and safety of CK0802 Tregs for treatment of refractory GVHD (graft-versus-host disease)
- Trial name
- NCT07576699
- Testing
- CK0802 (Allogeneic, Cryopreserved, Cord blood-derived T-regulatory cells, cells that are not HLA matched)
- Volunteers
- 12 people
- Sponsor
- Cellenkos, Inc.
Kawasaki Disease, Steroid
A Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)
Background: Kawasaki disease (KD), most popular acquired heart disease in childhood, is characterized by diffuse vasculitis, especially on the middle-sized muscular arteries. IVIG and aspirin are currently standard treatment.
- Conditions
- Kawasaki Disease, Steroid, Immuoglobulin
- Trial name
- RAST (NCT03200561)
- Testing
- Prednisolone, immunoglobulin
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease
Donor Regulatory T Cells Infusion in Patients With Chronic Graft-versus-host Disease (GVHD)
The immune system has offensive and defensive capacities. In bone marrow transplantation, offensive cells in the donor grafts may attack host's organs, leading to a complication known as Graft versus Host Disease (GVDH).
- Conditions
- Chronic Graft-Versus-Host Disease, Acute Graft-Versus-Host Disease, Steroid Refractory Graft-Versus-Host Disease
- Trial name
- NCT01903473
- Testing
- Rapamycin, T regulatory cells
- Where
- 2 sites in Belgium
- Volunteers
- 19 people
- Sponsor
- University of Liege
Allogeneic Hematopoietic Stem Cell Transplantation
A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
The purpose of this study is to assess the initial activity, tolerability, safety and to identify a recommended dose and regimen of vedolizumab intravenous (IV) administered for treatment of steroid-refractory acute intestinal…
- Trial name
- NCT02993783
- Testing
- Vedolizumab
- Where
- 15 sites in United States, Belgium and 3 more
- Volunteers
- 17 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Hepatitis, Drug-Induced
Treatment Efficacy of Corticosteroids and Mycophenolate Mofetil in Patients With Immune Related Hepatitis
This clinical trial is to clarify and investigate the patterns of immune-related hepatitis and the optimal treatment choice for patients who are steroid-dependent.
- Trial name
- I-HEP (NCT04810156)
- Testing
- Mycophenolate Mofetil, Solu-Medrol, Ursodeoxycholic acid
- Where
- 5 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Inge Marie Svane
Ulcerative Colitis
Optimising Infliximab Induction Therapy for Acute Severe Ulcerative Colitis
The purpose of this study is to identify whether an Accelerated or Intensified Infliximab induction regimen is superior to Standard induction in Acute Severe Ulcerative Colitis in an open label multi-centre randomised controlled…
- Trial name
- PREDICT UC (NCT02770040)
- Testing
- Infliximab
- Where
- Australia
- Volunteers
- 138 people
- Sponsor
- Austin Health